Rokid Founder Mingo Zhu Responds: Company Restructuring and Joint-Stock Reform Proceeding at Normal PaceWallstreetcn·Apr 8 at 08:57 AM003008+2.04%300091+1.65%
GZBL: Net profit for the third quarter was 4.9798 million yuan, a year-on-year increase of 559.90%Zhitong·Oct 24, 2025 at 06:03 AM002424+0.88%
The concept of innovative drugs continues to rebound, with GZBL and Luoxin Pharmaceutical both hitting the daily limitZhitong·Oct 15, 2025 at 08:59 PM002793+1.54%002424+0.88%
The traditional Chinese medicine sector fluctuated and surged, with GZBL hitting the limit upZhitong·Oct 15, 2025 at 08:45 PM002424+0.88%
GZBL: The clinical trial application for Tangning Tongluo tablets has been approvedZhitong·Oct 15, 2025 at 04:34 AM002424+0.88%
GZBL: The capacity expansion and technological transformation project has been completed and put into production, increasing the processing capacity of traditional Chinese medicinal materials to 60,000 tons per yearZhitong·Aug 19, 2025 at 07:13 AM002424+0.88%
GZBL: Net profit of 51.8346 million yuan in the first half of 2025, a year-on-year decrease of 40.73%Zhitong·Aug 19, 2025 at 05:27 AM002424+0.88%
The innovative drug concept is repeatedly active, and Staidson BioPharm has reached a new historical high36Kr·Jul 1, 2025 at 08:57 PM688321+1.97%300204+4.92%
ST GZBL stock cancels other risk warnings and will be suspended for 1 day on June 27Zhitong·Jun 26, 2025 at 08:02 AM002424+0.88%
ST GZBL released its first-quarter performance, with a net profit attributable to shareholders of 24.1697 million yuan, a decrease of 53.25%Zhitong·Apr 29, 2025 at 10:23 AM002424+0.88%
ST GZBL and other investors establish a new company including health food production businessZhitong·Feb 13, 2025 at 10:33 PM002424+0.88%
The national launch meeting for the Phase III clinical study of Guizhou BaiLing TangNing TongLuo tablets was successfully heldZhitong·Jan 18, 2025 at 07:22 AM002424+0.88%
